Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study

Title
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study
Author(s)
이경희Kang hye jin[Kang hye jin]Ryu min hee[Ryu min hee]Kim kyoung mee[Kim kyoung mee]Park young soo[Park young soo]Chol jene[Chol jene]Ryoo baek yeol[Ryoo baek yeol]Kim woo ho[Kim woo ho]Im seock ah[Im seock ah]Bang yong jue[Bang yong jue]Park se hoon[Park se hoon]Lee jae hyuk[Lee jae hyuk]Chung ik joo[Chung ik joo]Bae han ik[Bae han ik]Kim jong gwang[Kim jong gwang]Song hong suk[Song hong suk]Kwon hyuk chan[Kwon hyuk chan]Baek jin ho[Baek jin ho]Shin dong bok[Shin dong bok]Lee kyoung eun[Lee kyoung eun]Kang yoon koo[Kang yoon koo]
Keywords
TYROSINE KINASE INHIBITOR; OF-FUNCTION MUTATIONS; C-KIT MUTATION; RANDOMIZED-TRIAL; DOSE IMATINIB; IN-VITRO; MESYLATE; DIAGNOSIS; GROWTH; PROGRESSION
Issue Date
201204
Publisher
INFORMA HEALTHCARE
Citation
ACTA ONCOLOGICA, v.51, no.4, pp.528 - 536
Abstract
Purpose. To assess the efficacy of imatinib for different tumor genotypes in Korean patients with advanced gastrointestinal stromal tumors (GIST). Material and methods. Clinical data were collected from 370 consecutive patients with locally advanced unresectable, metastatic, or recurrent GIST treated with imatinib 400 mg/day between August 2001 and December 2007 at 20 Korean institutions. Tumor genotypes were determined for 290 patients by direct DNA sequencing of KIT exons 9, 11, 13, and 17, and PDGFRA exons 12, 14, and 18. Results. Of 290 patients assessed for genotype, 261 (90.0%) had mutations in KIT : 222 (76.6%) in exon 11, 35 (12.1%) in exon 9 and two each (0.7%) for exons 13 and 17. Four patients (1.4%) had mutations in the PDGFRA gene: one in exon 12, and three in exon 18. Twenty-five patients (8.6%) had no detectable mutations. The best responses of the 235 patients with measurable lesions were: 15 complete response (6.4%), 126 partial response (53.5%), 86 stable disease (36.6%), and eight progressive disease (3.4%). Patients with KIT exon 9 mutations, compared with patients with KIT exon 11 mutations, had a lower objective response rate (36.7% vs. 63.6%, p = 0.007) and a shorter progression-free survival (median 28.7 months vs. 49.4 months, p = 0.001). No statistical difference in overall survival was observed between these genotypes. Conclusion. This study confirms that imatinib efficacy is dependent on genotype in Korean GIST patients, consistent with results demonstrated by Western patients with GIST.
URI
http://hdl.handle.net/YU.REPOSITORY/28608http://dx.doi.org/10.3109/0284186X.2011.636753
ISSN
0284-186X
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE